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DNA repair in blood cells was observed to be suboptimal in cancer patients at diagnosis, including colorectal cancer
(CRC). To explore the causality of this phenomenon, we studied the dynamics of DNA repair from diagnosis to 1 yr follow-
up, andwith respect to CRC treatment. Systemic CRC therapy is targeted to DNA damage induction and DNA repair is thus
of interest. CRC patients were blood-sampled three times in 6-mo intervals, starting at the diagnosis, and compared to
healthy controls. DNA repair was characterized by mRNA levels of 40 repair genes, by capacity of nucleotide excision repair
(NER), and by levels of DNA strand breaks (SBs). NER and base excision repair genes were significantly under-expressed
(P< 0.016) in patients at diagnosis compared to controls, in accordance with reduced NER function (P¼0.008) and
increased SBs (P¼ 0.015). Six months later, there was an increase of NER capacity, but not of gene expression levels, in
treated patients only. A year from diagnosis, gene expression profiles and NER capacity were significantly modified in all
patients andwere no longer different from thosemeasured in controls. All patients were free of relapse at the last sampling,
sowewere unable to clarify the impact of DNA repair parameters on treatment response. However, we identified a panel of
bloodDNA repair-relatedmarkers discerning acute stage of the disease from the remission period. In conclusion, our results
support a model in which DNA repair is altered as a result of cancer. © 2014 Wiley Periodicals, Inc.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most
frequently occurring malignancies in Western coun-
tries. The genetic basis of hereditary forms ("6% of all
cases) is relatively well explored while for sporadic
forms ("75% of all cases) there is still a lack of
knowledge about the genetic–epigenetic–environ-
mental triggers of the disease. More importantly,
CRC has high mortality worldwide due to the
insufficient treatment efficacy and a lack of predictive
markers [1]. Only approximately half of CRC patients
will be cured using currently available therapies [2]. A
commonly used conventional regimen for CRC
treatment is based on the synergistic action of two
DNA-damaging agents: 5-fluorouracil (5FU) and
oxaliplatin. In response to this treatment, cells
activate a range of resistance-promoting mechanisms
including the DNA repair pathways [3]. Some of the
optimal biomarkers might be thus found within the
DNA repair network.
Abbreviations: 5FU, 5-fluorouracil; BPDE, (þ)-anti-Benzo[a]pyrene-
7,8-dihydrodiol-9,10-epoxide; BER, base excision repair; CRC, color-
ectal cancer; CV, coefficient of variation; DDR, DNA damage response;
HR, homologous recombination; MMR, mismatch repair; NER,
nucleotide excision repair; PBMCs, peripheral blood mononuclear
cells; PCA, principal component analysis; SBs, strand breaks.
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The present study represents a continuation of our
previous report, where we showed that peripheral
bloodmononuclear cells (PBMCs) collected fromCRC
patients at the time of diagnosis exhibited elevated
genetic instability. Specifically, they had increased
levels of DNA strand breaks (SBs) and low DNA repair
capacity accompanied by altered expression of repair
genes [4]. The suboptimal DNA repair capacity in
PBMCs of cancer patients is now well documented
and observed inmultiple cancer types [4]. Thus, there
is a large body of evidence obtained in case–control
studies supporting the association between cancer
and a decrease in the ability of blood cells to protect
against DNA damage. However, a sampling of the
patients at one time point does not bear information
about the causality of this phenomenon and so it
remains to be established whether low DNA repair is
one of the susceptibility factors for sporadic CRC, or it
is a consequential effect of the disease. On the other
hand, it is known that DNA repair capacity detectable
in PBMCs is significantly related to the repair capacity
of colorectal tissue [5,6]. These observations givemore
confidence for using blood as a surrogate for cancer-
target tissue to studyDNA repair involvement inCRC.
Subsequently, a few recent studies provided evidence
that tumor tissuemaintains comparable base excision
repair (BER) capacity and slightly elevated capacity
of nucleotide excision repair (NER) as compared to
adjacent healthy colorectal mucosa, although there
is a differential mRNA expression of DNA repair
genes [6–8]. Impaired excision repair, thus, may not
contribute to the malignant transformation of the
colon, but rather might be involved in the treatment
response of the patients.
Conventional therapy of CRC, based on the
mutagenic properties of anticancer drugs, is expected
to be more harmful to fast growing tumor cells than
to normal cells. However, details of the effects of
radiotherapy and chemotherapy on the cellular and
molecular functions of the tumor and normal cells are
still unexplored. Almost all DNA repair pathways are
presumably involved in the cellular response to CRC
treatment. 5FU-mediated DNA lesions are recognized
by the BER and the mismatch repair (MMR) sys-
tems [9]. Oxaliplatin binds to nucleobases forming
intra- and inter-strand crosslinks. The former are
eliminated mainly by the NER pathway while the
latter require NER together with cross-link repair
activity, translesion synthesis, and homologous re-
combination repair (HR) [10]. Understanding the
involvement of DNA repair processes in the response
of cancer cells to antineoplastic drugs is crucial for the
design of improved therapy regimens and for the
prediction of therapeutic response in CRC.
The present exploratory study was aimed to address
several questions: (i) Do variations in DNA repair
contribute to the risk of developing sporadic CRC, or
are they rather a consequence of the systemic disease?
(ii) Is the DNA repair response to CRC treatment
measurable at the mRNA/functional level? (iii) Is it
induced or suppressed by the systemic genotoxic
exposure mediated by chemotherapy? In an attempt
to answer these questions, we have designed a
prospective study in which sporadic CRC patients
were blood-sampled at the diagnosis (i.e., active
disease), 6 mo, and 1 yr later (i.e., covering the tumor
resection, administration of chemotherapy, either
neoadjuvant or adjuvant, and remission) and were
compared with an healthy population. The dynamics
of DNA repair over a 1 yr period and with respect to
ongoing CRC treatment were analyzed. All main
repair pathways including excision repair (BER, NER,
and MMR), repair of double-strand breaks (HR and
non-homologous end joining), and DNA damage
response (DDR) were characterized at gene expression
levels. NER, themost deregulated pathway in patients
observed by us, was also studied using a functional
assay and through measuring SBs accumulation.
MATERIALS AND METHODS
Study Population
Incident CRC cases were recruited in the Czech
Republic between 2008 and 2010. Patientswere newly
diagnosed and histologically confirmed for CRC.
Eighty-three patients were initially recruited for the
study but only 39 (47%) attended all the three
planned blood samplings. Reasons for dropout were:
(i) 7 (8%) patients died before third sampling, (ii) 10
(12%) patients moved and were treated in other
hospitals or interrupted therapy for unspecified
reasons, (iii) 19 (23%) patients missed one out of
the three samplings or did not attend regular hospital
follow-up at agreed times, or the material provided
did notmeet the quality standards required, and (iv) 8
(10%) patients were excluded because they were
found not to be primary cancer cases. No other
selection of patients was performed. Forty-seven
controls were recruited among individuals who had
never been diagnosed with any cancer and did not
manifest any relevant systemic disease, nor had any
known significant exposure to potentially harmful
chemicals. Study subjectswere all of Caucasian origin.
They signed a written informed consent with the
study in accordance with the Helsinki declaration.
The Ethics committees of participating hospitals
approved the study. Trained personnel interviewed
the study subjects using a structured questionnaire for
lifestyle habits, body mass index, diabetes, and
family/personal history of cancer. Expression analysis
and functional assays could not be performed on all
patients, due to various reasons, that is, viability of
PBMCs or quality of RNA. For each analysis, the actual
number of examined cases is therefore specified.
Study Design
Blood samples were collected from patients three
times: at diagnosis, that is, before tumor resection and
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administrating any therapy (T0); 6 mo after tumor
resection, that is, approximately 6 mo from adminis-
tration of chemotherapy (T1); and after 1 yr, during
the regular follow-up appointment (T2). At T1 all
patients had completed the planned chemotherapy,
except for seven patients who received chemotherapy
for additional 1 or 2 mo. In eight patients, no therapy
was administered. At T2, all patients were free of
relapse.
Blood Processing
Blood samples were drawn into heparin and EDTA
vacutainers, and kept at 48C until processed within
3h. PBMCs from EDTA tubes were isolated on Ficoll–
Paque PLUS (GE Healthcare Life Sciences, Prague,
Czech Republic) and stored in TRIzol (Invitrogen,
Carlsbad, CA) at $808C until RNA extraction. PBMCs
from heparin tubes were isolated onHistopaque-1077
(Sigma–Aldrich, St. Louis, MO), counted, suspended
in full medium (RPMI 1640, 2mM L-glutamine, 10%
FBS, 0.2% penicillin/streptomycin, 1.5% phytohe-
magglutinin) and incubated at 378C for 20h to
stimulate mitosis. PBMCs were then processed for
DNA damage and DNA repair analysis.
DNA Strand Breaks
The level of SBs in DNA was evaluated by the
alkaline comet assay [11]. Experimental conditions
were as follows: lysis (2.5M NaCl, 100mM EDTA,
10mM Tris, 1% TritonX-100, 10% DMSO, pH 10,
%1h, 48C), alkali treatment (300mM NaOH, 1mM
EDTA, pH 13, 20min, 48C), electrophoresis (300mM
NaOH, 1mM EDTA, pH 13, 20min, 48C, 1.3V/cm),
and neutralization (0.4M Tris–HCl, pH 7.5, 2&
10min). Data are reported as tail DNA%, determined
as an average of 100 randomly selected comets from
two parallel slides per experimental point. Repeati-
bility of the assay was checked by repeated measuring
of 12 randomly chosen samples and obtained values
were in agreement (Spearman’s R¼0.76, P¼0.028).
Nucleotide Excision Repair Capacity
NER capacity was analyzed as the level of SBs
generated by the incision of (þ)-anti-Benzo[a]pyrene-
7,8-dihydrodiol-9,10-epoxide (BPDE)-adducts in cul-
tured PBMCs of study participants. The detailed
protocol is described in Slyskova et al. [11]. Briefly,
PBMCs were treated with 1mM of BPDE for 30min at
378C. BPDE was washed out and PBMCs were further
cultured and harvested immediately after the treat-
ment and at 1, 2, and 4h after the treatment.
Untreated PBMCs were cultured in parallel. For each
time point, the SBs level of the untreated PBMCs was
subtracted. The NER capacity was expressed as the
difference between the level of SBs measured imme-
diately after the BPDE treatment, and thehighest level
of SBs detected within 4h of culturing. Data are
presented as tail DNA%. Repeatibility of the assay was
checked by repeated measuring of 16 samples and
obtained results were in agreement (Spearman’s
R¼0.61, P¼0.012).
Gene Expressions
A panel of 40 genes (Supplementary Table S1) were
selected from the list of all known DNA repair
genes [12]. Total RNA was isolated using TRIzol
(Invitrogen). RNA integrity was between 8.0 and
10.0 units. cDNA was synthesized from 0.5mg of RNA
using the RevertAidTM First strand cDNA synthesis kit
(Fermentas, Ontario, Canada). cDNA was preampli-
fied and qPCR was performed using the BioMarkTM
HD System (Fluidigm) and using FAM-MGB assays
(Primer Design, Southampton, UK) as described pre-
viously [6]. TOP1 was the reference gene selected by
Normfinder usingGenEx Enterprise software (MultiD,
Goteborg, Sweden). Data were converted to relative
quantities and transformed to log2 scale. The repeat-
ibility of gene expression assays was calculated by
mixed ANOVA, comparing the values obtained in two
different experiments in 2 days for each assay. All assays
showed high degree of precision. The results are report-
ed in Supplementary Table S1 for each assay separately.
Data Analysis
Statistical analysis was conducted using R environ-
ment version 2.15 (open tool). Gene expression data
were pre-processed with GenEx Enterprise. DNA
damage and DNA repair capacity were consistent
with the Gaussian distribution, and so were the gene
expression data when log transformed. Student’s
t-test, paired t-test, ANOVA and Pearson’s rank
correlation coefficient were used to compare means
and calculate bivariate correlations. Statistical tests
were performed at 5% level of statistical significance.
Gene expression data are presented as fold-changes
relative to the reference samples, calculated using
linear models and the empirical Bayes method as
implemented in the “limma” package in the Bio-
conductor suite (open tool). P-values were adjusted
according to the Benjamini–Hochberg method. Prin-
cipal Component Analysis (PCA), Dynamic PCA,
Hierarchical Clustering (HCL), and Kohonen self-
organizing map analysis (SOM) of size 2&1, with
parameters: 0.1 learning rate, 2 neighbors, and 3000
iterations were used to analyze gene expression
profiles between patients and controls and between
different samplings in patients. The k-means algo-
rithmwas used to classify genes into clusters based on
their expression profiles over the three time points,
considering the patients clinical characteristics.
RESULTS
Study Population
Patients and controls did not differ significantly for
any recorded confounders, except for family history of
cancer, which was more prevalent among patients
(P¼0.01). The clinical, biological, and lifestyle
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characteristics of the study population, as well as an
overviewof the administered therapies, are summarized
in Table 1. All patients underwent surgical resection
of the tumor. Eighteen patients (46%) received neo-
adjuvant therapy prior to resection. Neoadjuvant
therapy included the following regimens: two patients
received radiotherapy (6MeV X-rays, 45–46Gy total
dose in 23–25 fractions), three patients received pre-
operative chemotherapy without radiotherapy (FOL-
FOX or capecitabine), and 13 patients received a
combined regimen. Twenty-two patients (56%) re-
ceived adjuvant systemic therapy; nine of them were
given 5FU-based therapy, while 13 received a combina-
tionof 5FUandoxaliplatin. Adjuvant therapywas given
over a period of 1–8 mo. Tumor relapse after the
treatment was not detected in any of the patients. Eight
patients did not receive any systemic treatment.
Case–Control Study
DNA repair genes expression
Twenty-seven CRC cases and 38 controls were
analyzed for the expression of 40 DNA repair genes,
sampled at diagnosis and before any treatment
intervention (T0). Patients had different expression
levels of BER and NER genes compared to controls:
four out of nine BER genes (APEX1, NTHL1, PARP1,
and MPG) and 10 out of 19 NER genes (RPA1, RPA2,
RPA3, CDK7, DDB1, DDB2, XPA, XPD, ERCC8, and
RAD23B) had significantly decreased levels in pa-
tients. Only LIG3 (BER) was increased in patients as
compared to controls. Fold-changes and P values are
reported in Supplementary Table S2. The dendogram
in Figure 1, performed byHCL, discriminates between
patients and controls by expression profiles of all 40
repair genes. The same discrimination was observed
for the NER genes only (data not shown).
NER capacity and SBs
Functional assays were performed for 31 CRC cases
and 38 controls. NER capacity was significantly lower
in the CRC patients analyzed at T0 compared to the
controls (mean' SD; 9.9'7.5 and 15.5'13.6, re-
spectively; t-test P¼0.008; Figure 2A), and the
patients had significantly higher levels of SBs than
Table 1. Study Population Characteristics
Characteristics Category CRC patients (n¼ 39) Controls (n¼47) P-value
Sex Female 15 24 0.25
Male 24 23
Age (years) Mean' SD 64.5' 10.5 64.2'13.7 0.94
Median 65 62.5
Range 32–81 33–87
Body mass index Mean' SD 27.6' 4.4 26.1' 3.6 0.14
Median 27.1 25.1
Range 17.6–37.3 20.7–34.7
Smoking status Non-smoker 27 38 0.72
Smoker 7 8
Alcohol consumption No 11 17 0.74
Yes 22 29
Diabetes No 26 43 0.08
Yes 7 3
Cancer in family No 13 31 0.01
Yes 21 15
CRC in family No 28 36 0.55
Yes 3 6
Tumor localization Colonþ rectosigmoideum 19 —
Rectum 20 —




Grade I 2 —
II 25 —
III 12 —
Therapy None 8 —
Neoadjuvant 18 —
Adjuvant 22 —
Neoadjuvantþ adjuvant 11 —
Regimen of adjuvant 5FU 9 —
therapy 5FUþ oxaliplatin 13 —
Significant differences are shown in bold.
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the controls (25.6'21.4 and 13.9'13.8, t-test
P¼0.015; Figure 2B).
Longitudinal Study
Changes in DNA repair genes expression during 1 yr of
follow-up
Twenty-seven patients analyzed at T0were sampled
two more times with at 6-mo intervals (T1 and T2).
Expression of the majority of the studied genes did
not change appreciably between T0 and T1 but
substantially changed at T2. PCA of all 40 studied
genes revealed similar expression patterns of samples
obtained at T0 and T1while the expression at T2had a
significantly different pattern and the samples were
organized in a distinct cluster together with controls
(Figure 3). To identify differentially expressed genes
that best discriminate both clusters, dynamic PCA in
combination with Kohenen SOM was used. Six genes
(BER: LIG3, NER: RPA3, CDK7, DDB2, HR: NBN, and
DDR: CHEK2) were found to be responsible for the
aggregation of patients into two distinct clusters
(Figure 4).
DNA repair genes expression over time in relation to
therapy
The k-means algorithm was used to correlate
the gene expression levels over time to treatment
(untreated vs. treated patients) and to the different
regimens of adjuvant therapy (5FU vs. 5FUþ
oxaliplatin). Four main clusters were generated based
on the Cq delta values representing the differences
between T1–T0 and T2–T1 (Supplementary Figure 1).
A trend line for the four clusters was constructed and
each cluster was also represented by a heatmap
showing for each gene the expression values over
time. The heatmap revealed great variability in the
expressiondynamics of the studied genes, particularly
in the T1–T2 interval. The expression of the majority
of the genes did not differ between treated and
untreated patients, except for three genes. The BER
gene MUTYH mRNA levels increased in adjuvantly
treated patients but was reduced in untreated. POLB
(BER) and XPB (NER) had constant expression over
time in treated patients, butwere upregulated fromT0
to T2 in untreated patients (Supplementary Figure 1).
No differences were observed between therapy regi-
mens of 5FUþoxaliplatin versus 5FU only.
Changes in NER capacity and SBs during 1 yr of follow-up
NER capacity and SBs were compared between the
three samplings in a group of 27 patients. NER
capacity increased significantly between T0 and T1,
and did not change further between T1 and T2 (T0:
9.9'7.5, T1: 15.8'13.2, T2: 11.2'6.9, ANOVA
P¼0.002; Figure 2A). NER capacity at T1 and T2 did
Figure 1. Hierarchical clustering of CRC patients sampled at the diagnosis (T0) and healthy controls according to
the expression profiles of 40 DNA repair genes.
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not differ from that in the controls (t-test P¼0.87 and
P¼0.10, respectively). SBs increased gradually, with
the largest rise being observed between T1 and T2 (T0:
25.6'21.4, T1: 29.2'17.1, T2: 41.8'12.8, ANOVA
P<0.001; Figure 2B). At all the three time points, SBs
level was significantly higher in cases than in the
controls (t-test P<0.001). P values for comparisons
between each sampling in patients computed by
paired t-test are reported in Supplementary Table S3.
NER capacity and SBs over time in relation to therapy
NER capacity increased over time in adjuvantly
treated patients (ANOVA P¼0.01), while the trend in
untreated patients was not significant (ANOVA
P¼0.08; Figure 5A). This trend was significant also
for patients receiving neoadjuvant treatment (AN-
OVA P¼0.02). No differences in NER capacity were
seen after stratification for treatment regimen: 5FU
(ANOVA P¼0.07) and 5FUþoxaliplatin (ANOVA
P¼0.19). SBs increased over time in all patients
irrespectively of the treatment. Figure 5B displays SBs
values over time in untreated (ANOVA P<0.001) and
adjuvantly treated patients (ANOVA P¼0.05), and
the same trend of increasing SBs was observed for
neoadjuvantly treated patients (ANOVA P¼0.04). By
stratifying adjuvantly treated patients, it was found
that the degree of SBs was not affected by 5FU
treatment (ANOVA P¼0.78), but increased with the
5FUþoxaliplatin regimen (T0: 19.0'22.4, T1:
28.6'21.6, T2: 42.4'14.1, ANOVA P¼0.047).
Paired t-test P values for comparisons between each
sampling in patients stratified for different treatments
are reported in Supplementary Table S3.
DISCUSSION
The present study was focused on characterizing
differences in DNA repair between CRC patients and
cancer-free population. Subsequently, defined im-
pairment of DNA repair in cancer patients was
Figure 2. NER capacity (A) and SBs (B) in CRC patients measured in
three consecutive samplings at 6-mo intervals starting from the
diagnosis (T0, T1, and T2) and of healthy controls. Figure shows
mean' SD and ANOVA P values.
Figure 3. Principal component analysis of gene expression levels of 40 DNA repair genes analyzed in CRC patients
at three time points (T0, T1, and T2) and in control population.
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followed-up during a post-treatment period, with
samplings at 6 mo after tumor resection and
chemotherapy administration, and an additional
sample 6 mo later. This study should reflect changes
in the DNA repair proficiency in patients under the
genotoxic stress of the anti-cancer treatment. We
have characterized DNA repair processes in blood
samples of CRC patients. PBMCs are considered to be
representatives of the general condition of the
organism and we have shown that their DNA repair
capacity reflects that of colonicmucosa [6]. Therefore,
PBMCs represent potential surrogates of CRC target
tissue, with the great advantage that if repeated
biopsies are difficult to obtain, repeated blood
samplings are feasible and much better suited for
therapy monitoring.
DNA Repair in Patients Versus Controls
In the present case–control study, we have identi-
fied genes that were differentially expressed between
CRC patients at diagnosis and controls. Several BER
and themajority of the studiedNERgeneswere under-
expressed in CRC patients. We evaluated NER also on
functional level to determine if the reduced mRNA
expression levels were concomitant with reduced
functional capacity of the pathway. Decreased NER
capacity in patients was confirmed and was accompa-
nied by increased levels of SBs. These findings are
consistent with our previous observations of CRC
patients sampled at diagnosis having lower NER
capacity and higher DNA damage than controls [4].
A large body of evidence is now available on impaired
NER in patients diagnosed with different types of
malignancies, as reviewed by us [4] and by [13].
However, these are case-control studies with no
further indication on causality of this phenomenon
in relation to cancer onset.
DNA Repair in Patients' Follow-Up
We designed a longitudinal study to follow up the
CRC patients from diagnosis to 1 yr in three different
Figure 4. Identification of themost significant genes responsible for division of samples into two separate clusters.
The color coding is the identical with the one in Figure 3. Kohenen self-organizing map analysis (A) and three-
dimensional principal component analysis (B) based on the mean-centered differential gene expression profiles of
LIG3, RPA3, CDK7, DDB2, NBN, and CHEK2.
Figure 5. Subgroups of untreated patients and adjuvantly treated
patients compared for changes in NER capacity (A) and DNA SBs levels
(B) as analyzed in three consecutive samplings obtained at 6-mo
intervals (T0, T1, and T2). Figure shows mean' SD and ANOVA
P values.
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samplings obtained 6 mo apart. Interestingly, while
expression profiles at diagnosis and 6 mo later were
substantially similar for the 40 analyzed genes,
significant changes in mRNA levels were observed at
the third sampling obtained 12 mo after diagnosis. At
that time point, patients were considered “cured” and
there were no cases in the study group that relapsed.
We can hypothesize that the expression profiles
of DNA repair genes reflected the disease activity.
Indeed, patients’ expression profiles a year from
diagnosis were comparable to those of the healthy
subjects. NER capacity showed a similar tendency.
From reduced level in patients at the time of
diagnosis, NER capacity increased during the post-
treatment period between diagnosis and 1 yr later,
eventually matching the level of the healthy subjects.
Different results were obtained for the comparison of
SBs levels overtime in patients. SBs were twofold
higher in patients at diagnosis compared to controls,
and their level further increased reaching threefold
difference a year fromdiagnosis. This accumulation of
SBs was independent of the presence of the tumor in
the body as well as treatment with DNA-damage
inducing drugs. Possibly some other clinical or
biological parameters that we have not controlled
for may be responsible for this late effect.
The dynamics of DNA repair capacity were previ-
ously studied in healthy individuals by comparing
BER and NER activities in six repeated samplings over
a 5-mo period [14]. The values positively correlated
and the coefficient of variation (CV) was 27% for
BER and 49% for NER, respectively. Intra-individual
variability of NER capacity was evaluated also by us
in a pilot study of 16 healthy subjects sampled twice
6 mo apart. Values of two independent samplings
significantly positively correlated and the CV of 20%
was much lower than the inter-individual variability
observed in our recent study on 340 healthy individ-
uals (CV 84% for BER and 90% for NER; unpublished
data). Similar observations were also reported in the
study by Vogel et al [15]. DNA repair capacity thus
seems to be a characteristic parameter for each
individual (but having a rather high variability across
the general population). Here, we showed that this
hypothesis based on healthy population is not
applicable in cancer patients. In fact, in the present
study we showed that cancer patients undergoing
anti-cancer treatment displayed significant changes
in DNA repair overtime, between the diagnosis and
the recovery period 1 yr later.
Only a few studies have examined DNA repair
prospectively to elucidate the role of this process in
cancer development. The expression levels of DNA
repair genes OGG1, NEIL1,MUTYH, ERCC1, and XPD
were not associated with subsequent risk of getting
lung cancer, and it was proposed that mRNA levels
should be regarded as a biomarker of exposure to
oxidative stress rather than a marker of inborn DNA
repair capacity [16,17]. Quite the opposite was
concluded by Paz-Elizur et al. [18], who analyzed
OGG1 activity in lung cancer patients at 1 yr follow-
up starting at diagnosis and reported a lack of an effect
of the tumor on OGG1 activity, suggesting the
inherent characteristic of this parameter. Our study,
in contrary to previous ones, used a multivariate
approach to search for biomarkers that best charac-
terize an individuals’ DNA repair status. It is becoming
imperative to classify diseases not on the basis of a
single biomarker, but on the basis of a set ofmolecular
markers [19]. This is expected to be more robust and
reliable than using any single biomarker because of
their generally high variability. Changes in individual
parameters will not necessarily result in a significant
change of the entire pattern. Using this approach, we
have seen that a decreased DNA repair status was
strongly related to disease at diagnosis, but after the
follow-up was no longer detectable. We have charac-
terized a set of DNA repair-related parameters, which
blood levels could distinguish between a condition of
acute CRC versus disease in remission. The mRNA
levels of six DNA repair genes (LIG3, RPA3, CDK7,
DDB2,NBN, and CHEK2) together with NER capacity,
if verified on a larger and independent population,
might represent a panel of CRC related biomarkers.
DNA Repair in Relation to Therapy
NER capacity was increased upon tumor resection
in all patients, but this trend was statistically
significant only in patients administered to chemo-
therapy. In this context it is noteworthy that the
P values observed for the increase in DNA repair in
untreated patients were of borderline significance.
An increase in the probability of these findings by
enlarging the study group cannot be ruled out.
Therefore, it is difficult at present to clearly distin-
guish whether the enhancement of NER capacity is a
consequence of surgical tumor elimination, a defense
reaction of normal cells against a systemic treatment,
or both. Mutagenic activity of radio- and chemo-
therapeutics poses a challenge to not only the tumor,
but also normal cells, that need to adjust their cellular
functions in order to protect their genetic integrity.
Indeed, several studies have shown that DNA repair
processes are induced by genotoxic stress [20–23]. In
our study group, an increase in theNER capacity at the
end of treatment was not accompanied by an increase
in the NER genes transcription, except for XPF and
XPG. These two might be the main activators of NER
function. In fact, endonucleases are critical compo-
nents of NER and their knockdown dramatically
reduces NER activity [24]. In this context, we cannot
neglect the role of post-transcriptional [25,26] and
post-translational [27–30] modifications in DNA
repair regulation. At the mRNA level, only 3 out
of 40 genes showed differential behavior between
treated and untreated subjects, and those were
involved again in the BER and NER pathways. BER
gene MUTYH (MutY Homolog E. coli) increased its
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expression over time in treated patients and remained
stable in untreated patients. On the contrary, POLB
(Polymerase Beta) involved in BER and NER gene XPB
(Xeroderma Pigmentosum B) showed increased
expression over time in untreated patients only.
Although these differences did not seem to have
any effect on the immediate response to therapy, it
cannot be excluded that they may play some role in
long-term survival. Above genes have been observed
to be implicated in CRC development. Aberrant
MUTYH glycosylase has been linked to one type of
CRC [31], and POLB is mutated in about 50% of
human cancers [32], including CRC [33]. Also,
therapeutic downregulation of POLB activity was
recently considered in order to meet better treatment
response [34], and its mRNA levels have been
proposed to be a prognostic indicator in CRC
treatment [35].
So far, few studies have examined DNA repair in
relation to anti-cancer therapy response and survival,
but they usually sampled patients only once before
therapy. Jewell et al. studied melanoma patients and
reported that highermRNA levels of DNA repair genes
in biopsies were associated with a higher risk of
relapse [36].Wang et al. [37] found that elevated DNA
repair activity in peripheral lymphocytes correlated
with shorter survival in lung cancer. Similar tenden-
cies were reported by Asakawa et al. [38] in breast
cancer biopsies in which high DNA damage response
was linked with poor response to neoadjuvant
therapy. We were unable to analyze DNA repair
parameters in relation to the patients’ response to
therapy at endpoint since no post-treatment tumor
relapse was observed in the study group. Considering
the small size of the study population, further
stratifications for specific treatments would not
reach sufficient statistical power to draw strong
conclusions.
In summary, we described the dynamics of DNA
repair in blood cells of CRC patients in a time frame of
1 yr. DNA repair downregulation in the presence of
active disease, as reflected by quantitative PCR and
functional assays, was centered on two excision repair
pathways—BER andNER. One year after the diagnosis
and successful treatment, the downregulation was
not detectable anymore, and the patients exhibited a
molecular pattern of DNA repair similar to that of
healthy controls. DNA repair markers evaluated in
blood cells can be used to distinguish between an
acute and a post-treatment cancer-free condition,
thus reflecting the disease activity in CRC patients.
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